Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies based on proprietary herpes simplex virus (HSV) platform technology. The company's lead candidate RP1 is in Phase 3 trials for cutaneous squamous cell carcinoma and melanoma, with additional programs targeting solid tumors through combination approaches. As a pre-revenue biotech, the stock trades on clinical trial readouts, regulatory milestones, and cash runway visibility.
Replimune operates a classic clinical-stage biotech model with no current revenue. The company burns approximately $200M annually in operating cash to fund Phase 3 trials (IGNYTE and CERPASS studies) and earlier-stage pipeline development. Value creation depends on successful clinical trial outcomes demonstrating tumor response rates and progression-free survival benefits, followed by FDA approval and commercial launch. The oncolytic virus platform offers potential differentiation through direct tumor lysis and immune activation mechanisms. Monetization pathways include direct commercialization in oncology specialty markets, partnership deals with larger pharma companies, or acquisition. Current cash position of approximately $300M (based on 5.60 current ratio) provides estimated 18-24 month runway at current burn rate.
Phase 3 IGNYTE trial interim and final data readouts for RP1 in cutaneous squamous cell carcinoma (primary catalyst through 2026-2027)
Phase 3 CERPASS trial data for RP1 plus nivolumab in melanoma (secondary near-term catalyst)
FDA regulatory interactions, breakthrough therapy designations, or accelerated approval pathway discussions
Cash runway updates and equity financing announcements (dilution risk given negative FCF of $200M annually)
Partnership or licensing deal announcements with major pharma companies
Competitive clinical data from other oncolytic virus platforms or IO combination therapies
Binary clinical trial risk: Phase 3 trial failures would eliminate near-term value proposition and likely trigger significant equity dilution or strategic alternatives. Oncolytic virus platforms have mixed historical success rates with only T-VEC (Amgen) achieving approval in melanoma.
Competitive intensity in immuno-oncology: Crowded landscape with checkpoint inhibitors, CAR-T, bispecifics, and other IO modalities competing for same patient populations. RP1 must demonstrate differentiated efficacy or combination benefits to achieve meaningful market share.
Regulatory pathway uncertainty: FDA approval standards for IO combinations continue evolving, with increasing emphasis on overall survival endpoints rather than response rates, potentially extending development timelines and costs.
Direct competition from other oncolytic virus developers (Oncorus, Candel Therapeutics) and established IO franchises (Merck's Keytruda, BMS's Opdivo) in melanoma and CSCC indications
Risk of being acquired at depressed valuation if larger pharma partners develop competing internal programs or in-license alternative assets
Equity dilution risk: With $200M annual burn and estimated 18-24 month cash runway, company will require additional financing before Phase 3 data readouts. At current $600M market cap, meaningful dilution likely in next capital raise.
Going concern risk if Phase 3 trials fail and company cannot secure partnership or alternative funding, though current 5.60 current ratio suggests near-term liquidity adequate
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact biotech financing availability and M&A activity, affecting funding options and potential exit valuations. Oncology drug demand is non-discretionary and recession-resistant post-approval.
Rising interest rates negatively impact Replimune through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, particularly punitive for pre-revenue assets with 5-7 year commercialization timelines, (2) reduced risk appetite shifts capital away from speculative growth/biotech toward safer yield alternatives, (3) increased cost of capital for future equity raises needed to fund operations. The 10-year Treasury yield directly affects biotech valuation multiples, with 100bps rate increases historically compressing sector multiples by 15-25%.
Minimal direct credit exposure as the company has low debt (0.37 D/E ratio) and no commercial operations dependent on customer credit. However, broader credit market conditions affect biotech sector liquidity and ability to raise capital through equity or convertible debt offerings, critical given negative $200M annual cash burn.
growth/speculative - Attracts biotech-focused growth investors and hedge funds willing to accept binary clinical trial risk for potential multi-bagger returns if Phase 3 trials succeed. High volatility and pre-revenue status unsuitable for value or income investors. Recent 48% one-year decline reflects de-risking as clinical catalysts approach and sector rotation away from unprofitable growth names.
high - Clinical-stage biotech with no revenue exhibits extreme volatility around data readouts (typical 30-60% single-day moves on trial results). Six-month return of +36% followed by three-month decline of -17% demonstrates momentum-driven trading. Estimated beta above 1.5x relative to broader market, with idiosyncratic risk dominating systematic factors.
